Natural Product Model of Action Studies
Natural Product Model of Action Studies
批准号:
7195692
负责人:
CRAIG M CREWS
金额:
$28.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2009-02-28
关键词:
AffinityAngiogenesis InhibitorsAnti-Inflammatory AgentsAnti-inflammatoryAreaBindingBinding ProteinsBiochemicalBiologicalBiological FactorsBiologyCell DeathCellsCellular biologyChemicalsCloningCommunitiesComplexCyclosporinsCytotoxic agentDNA BindingDevelopmentDinophyceaeDrug Delivery SystemsEvaluationFK506GenerationsGenesGenetic TranscriptionGoalsI Kappa B-AlphaInflammatoryInvestigationKnowledgeLeadLearningLightMacrolidesMediatingMethodologyModelingMolecularNF-kappa BO,O-diisopropyl-S-benzylthiophosphatePharmacologic SubstancePlayProcessPropertyProtein OverexpressionProteinsProtocols documentationRNA InterferenceReagentRegulationReportingResearchRoleRouteSignal PathwaySignal TransductionSirolimusSourceStagingWorkamphidinolide BanalogbasecDNA Expressioncytotoxiccytotoxicitydisorder controldrug discoveryeponemycinepoxomicinfumagillinimmunoregulationinterestnovelparthenolidereceptortranscription factortumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Exploration of a natural product's mode of action often sheds light on basic areas of biology not easily studied by traditional approaches. This bioorganic strategy to cell biology has led to significant advances in the study of immunoregulation using the natural products, FK506, cyclosporin, and rapamycin. In addition, the investigation of how potent biologically active natural products work at the molecular level (through the identification of their intracellular protein receptors), can lead to the identification of key proteins within a complex intracellular process. These natural product target proteins are, by definition, 'pharmaceutically vulnerable' and thus can serve as novel drug targets.
This proposal focuses on the modes of action of two natural products; the anti-inflammatory fungal metabolite isopanepoxydone and the potent antitumor macrolide amphidinolide B isolated from an Okinawan dinoflagellate. Isopanepoxydone blocks the DNA binding activity of NF-kappaB, a key transcription factor that mediates pro-inflammatory signal-induced gene transcription. This is mediated via inhibition of I?B degradation, a protein that negatively regulates the activity of NF-kappaB. Although much is known about the downstream consequences of isopanepoxydone's anti-inflammatory action, the protein target of this natural product that lies upstream of IkappaB is unknown. Towards the goal of identifying the intracellular target of isopanepoxydone, we have modified our previously reported synthetic route to generate a biotinylated isopanepoxydone affinity reagent. Here, we present evidence for a 48kDa protein that covalently and specifically binds to this isopanepoxydone affinity reagent. The objective of this research is to understand the molecular mechanisms by which isopanepoxydone inhibits pro-inflammatory signal transduction through the purification, identification and characterization of this 48kDa isopanepoxydone binding protein.
The anti-tumor macrolide amphidinolide B is at an earlier stage in the mode of action elucidation process. We propose here a novel retrosynthetic disconnection strategy for the total synthesis of this potent natural product. This synthetic effort will also afford the facile generation of a biotinylated affinity reagent, with which we plan to purify, identify and clone amphidinolide B binding proteins. Biochemical and cell biological characterization of these amphidinolide binding proteins will confirm their role in mediating the potent cytotoxicity of the natural product. We have successfully employed this same chemical/biochemical/cell biological approach to identify and characterize the intracellular receptors of the antiangiogenic natural product, fumagillin, the anti-inflammatory agent, parthenolide, and the antitumor compounds, epoxomicin and eponemycin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing Tumor-specific PROTACs
-
批准号:10244943
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2019
-
负责人:CRAIG M CREWS
-
依托单位:
Developing Tumor-specific PROTACs
-
批准号:10470405
-
项目类别:
-
资助金额:$37.44万
-
财政年份:2019
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities
-
批准号:10518541
-
项目类别:
-
资助金额:$89.31万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Protein Degradation: A New Pharmaceutical Paradigm
-
批准号:9142301
-
项目类别:
-
资助金额:$89.35万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Protein Degradation: A New Pharmaceutical Paradigm
-
批准号:10250394
-
项目类别:
-
资助金额:$87.75万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
KRas Ligand Development
-
批准号:9023184
-
项目类别:
-
资助金额:$21.78万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Protein Degradation: A New Pharmaceutical Paradigm
-
批准号:9763483
-
项目类别:
-
资助金额:$85.11万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Protein Degradation: A New Pharmaceutical Paradigm
-
批准号:8955987
-
项目类别:
-
资助金额:$84.99万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities
-
批准号:10701073
-
项目类别:
-
资助金额:$89.87万
-
财政年份:2015
-
负责人:CRAIG M CREWS
-
依托单位:
Towards Mammalian Limb Regeneration
-
批准号:8536848
-
项目类别:
-
资助金额:$31.81万
-
财政年份:2010
-
负责人:CRAIG M CREWS
-
依托单位:
Towards Mammalian Limb Regeneration
-
批准号:7994509
-
项目类别:
-
资助金额:$31.52万
-
财政年份:2010
-
负责人:CRAIG M CREWS
-
依托单位:
Towards Mammalian Limb Regeneration
-
批准号:8288394
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2010
-
负责人:CRAIG M CREWS
-
依托单位:
Towards Mammalian Limb Regeneration
-
批准号:8322068
-
项目类别:
-
资助金额:$33.22万
-
财政年份:2010
-
负责人:CRAIG M CREWS
-
依托单位:
Towards Mammalian Limb Regeneration
-
批准号:8134803
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2010
-
负责人:CRAIG M CREWS
-
依托单位:
A MULTIPRONGED, PROTEIN DEGRADATION-BASED APPROACH TO INHIBIT HIV TRANSMISSION
-
批准号:7737777
-
项目类别:
-
资助金额:$46.68万
-
财政年份:2009
-
负责人:CRAIG M CREWS
-
依托单位:
A MULTIPRONGED, PROTEIN DEGRADATION-BASED APPROACH TO INHIBIT HIV TRANSMISSION
-
批准号:7940837
-
项目类别:
-
资助金额:$46.13万
-
财政年份:2009
-
负责人:CRAIG M CREWS
-
依托单位:
A MULTIPRONGED, PROTEIN DEGRADATION-BASED APPROACH TO INHIBIT HIV TRANSMISSION
-
批准号:8306916
-
项目类别:
-
资助金额:$45.93万
-
财政年份:2009
-
负责人:CRAIG M CREWS
-
依托单位:
Predoctoral Training at the Interface Chemistry and Biology
-
批准号:7887070
-
项目类别:
-
资助金额:$8.7万
-
财政年份:2009
-
负责人:CRAIG M CREWS
-
依托单位:
A MULTIPRONGED, PROTEIN DEGRADATION-BASED APPROACH TO INHIBIT HIV TRANSMISSION
-
批准号:8125128
-
项目类别:
-
资助金额:$45.94万
-
财政年份:2009
-
负责人:CRAIG M CREWS
-
依托单位:
Analysis of Tumorigenic Signaling Pathways with PROTACS
-
批准号:7691393
-
项目类别:
-
资助金额:$29.44万
-
财政年份:2006
-
负责人:CRAIG M CREWS
-
依托单位:
海外基金